View : 416 Download: 44

Salmonella Vaccine Vector System for Foot-and-Mouth Disease Virus and Evaluation of Its Efficacy with Virus-Like Particles

Title
Salmonella Vaccine Vector System for Foot-and-Mouth Disease Virus and Evaluation of Its Efficacy with Virus-Like Particles
Authors
Zhi, YongJi, Hyun JungGuo, HuichenLim, Jae HyangByun, Eui-BaekKim, Woo SikSeo, Ho Seong
Ewha Authors
임재향
SCOPUS Author ID
임재향scopus
Issue Date
2021
Journal Title
VACCINES
ISSN
2076-393XJCR Link
Citation
VACCINES vol. 9, no. 1
Keywords
foot-and-mouth diseaseVP1live attenuated Salmonella vectormucosal immunityvirus-like particleradiation mutation
Publisher
MDPI
Indexed
SCIE; SCOPUS WOS scopus
Document Type
Article
Abstract
Foot-and-mouth disease virus (FMDV) causes a highly contagious and devastating disease in livestock animals and has a great potential to cause severe economic loss worldwide. The major antigen of FMDV capsid protein, VP1, contains the major B-cell epitope responsible for effectively eliciting protective humoral immunity. In this study, irradiated Salmonella Typhimurium (KST0666) were used as transgenic vectors containing stress-inducible plasmid pRECN-VP1 to deliver the VP1 protein from FMDV-type A/WH/CHA/09. Mice were orally inoculated with ATOMASal-L3 harboring pRECN-VP1, and FMDV virus-like particles, where (VLPFMDV)-specific humoral, mucosal, and cellular immune responses were evaluated. Mice vaccinated with attenuated Salmonella (KST0666) expressing VP1 (named KST0669) showed high levels of VLP-specific IgA in feces and IgG in serum, with high FMDV neutralization titer. Moreover, KST0669-vaccinated mice showed increased population of IFN-gamma (type 1 T helper cells; Th1 cells)-, IL-5 (Th2 cells)-, and IL-17A (Th17 cells)-expressing CD4(+) as well as activated CD8(+) T cells (IFN-gamma(+)CD8(+) cells), detected by stimulating VLPFMDV. All data indicate that our Salmonella vector system successfully delivered FMDV VP1 to immune cells and that the humoral and cellular efficacy of the vaccine can be easily evaluated using VLPFMDV in a Biosafety Level I (BSL1) laboratory.
DOI
10.3390/vaccines9010022
Appears in Collections:
의과대학 > 의학과 > Journal papers
Files in This Item:
vaccines-09-00022-v2.pdf(3.7 MB) Download
Export
RIS (EndNote)
XLS (Excel)
XML


qrcode

BROWSE